NMR-guided fragment-based approach for the design of tRNALys3 ligands

Angewandte Chemie - International Edition

Volumn 46, Issue 24, 2007, Pages 4489-4491

  Chung, Florence ^a   Tisné, Carine ^a   Lecourt, Thomas ^a   Dardel, Frédéric ^a   Micouin, Laurent ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Aminoglycoside mimics; Drug design; Fragment based synthesis; RNA recognition; tRNA

Indexed keywords

DISSOCIATION; MOLECULAR STRUCTURE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RNA; SYNTHESIS (CHEMICAL);

DISSOCIATION CONSTANTS; FLOW INJECTION; STEM BINDERS;

LIGANDS;

ANTIVIRUS AGENT; LIGAND; LYSINE TRANSFER RNA; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CHEMISTRY; DRUG DESIGN; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ANTIVIRAL AGENTS; DRUG DESIGN; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; REVERSE TRANSCRIPTASE INHIBITORS; RNA, TRANSFER, LYS;

EID: 34250748537     PISSN: 14337851     EISSN: None     Source Type: Journal    
DOI: 10.1002/anie.200605201     Document Type: Article

References (28)

1. G. J. R. Zaman, P. J. A. Michiels, C. A. A. van Boeckel, Drug Discovery Today 2003, 8, 297-206.
2. a) E. Westhof, Biochimie 2006, 88, 931-933;
3. b) J. Poehlsgaard, S. Douthwaite, Nat. Rev. Microbiol. 2005, 3, 870-881.
4. N. W. Luedtke, Y. Tor in Small Molecule DNA and RNA Binders: From Synthesis to Nucleic Acid Complexes, Vol. 1 (Eds.: M. Demeunynck, C. Bailly, W. D. Wilson), Wiley-VCH, Weinheim, 2003.
5. R. Marquet, C. Isel, B. Ehresmann, Biochimie 1995, 77, 113-124.
6. Z. Zhang, S. M. Kang, C. D. Morrow, AIDS Res. Hum. Retroviruses 1998, 14, 979-988.
7. X. Wei, M. Götte, M. A. Wainberg, Nucleic Acids Res. 2000, 28, 3065-3074.
8. B. Francois, R. J. M. Russel, J. B. Murray, F. Aboul-ela, B. Masquida, Q. Vincens, E. Westhof, Nucleic Acids Res. 2005, 33, 5677-5690, and references therein.
9. a) X. Liu, J. R. Thomas, P. J. Hergenrother, J. Am. Chem. Soc. 2004, 126, 9196-9197;
10. b) J. R. Thomas, X. Liu, P. J. Hergenrother, J. Am. Chem. Soc. 2005, 127, 12 434-12 435;
11. c) J. R. Thomas, X. Liu, P. J. Hergenrother, Biochemistry 2006, 45, 10 928-10 938.
12. Phe: a) S. R. Kirk, Y. Tor, Bioorg. Med. Chem. 1999, 7, 1979-1991;
13. b) R. Szilaghi, S. Shahzad-Ul-Hussan, T. Weimar, ChemBioChem 2005, 6, 1270-1276;
14. c) N. E. Mikkelsen, K. Johansson, A. Virtanen, L. A. Kirsebom, Nat. Struc. Biol. 2001, 8, 510-514.
15. C. Tisné, F. Guillière, F. Dardel, Biochimie 2005, 87, 885-888.
16. P. Benas, G. Bec, G. Keith, R. Marquet, C. Ehresmann, B. Ehresmann, P. Dumas, RNA 2000, 6, 1347-1355.
17. C. Tisné, B. P. Roques, F. Dardel, J. Mol. Biol. 2001, 305-314, 443-454.
18. C. Tisné, B. P. Roques, F. Dardel, J. Biol. Chem. 2004, 279, 3588-3595.
19. a) D. C. Ress, M. Congreve, C. W. Murray, R. Carr, Nat. Rev. Drug Discovery 2004, 3, 660-672;
20. b) D. A. Erlanson, R. S. McDowell, T. O'Brien, J. Med. Chem. 2004, 47, 3463-3482.
21. For the NMR-spectroscopy-guided discovery of RNA binders, see: a) L. Yu, T. K. Oost, J. M. Schkeryantz, J. Yang, D. Janowick, S. W. Fesik, J. Am. Chem. Soc. 2003, 125, 4444-4450;
22. b) M. Mayer, T. L. James, J. Am. Chem. Soc. 2004, 126, 4453-4460.
23. The use of this "target-observation" strategy (as opposed to ligand-observation schemes, such as saturation transfer) is essential to filter out promiscuous binders, which interact through nonspecific electrostatic interactions with the highly charged nucleic acid. Promiscuous binders cause a general broadening of the NMR spectrum of the target, whereas specific binders induce only peak shifts, which allow the identification of the binding site. For a general review, see: H. O. Villar, J. Yan, M. R. Hansen, Curr. Opin. Chem. Biol. 2004, 8, 387-391.
24. For the NMR spectroscopic assignment of imino groups, see: C. Tisné, B. P. Roques, F. Dardel, J. Mol. Biol. 2001, 306, 443-454.
25. Lys3 ligands. However, they are too complex for a fragment-based approach. In contrast, compound 1 is an excellent 2-deoxystreptamine surrogate in the design of "RNA-friendly" compounds: L. Micouin, F. P. Dardel, C. Tisne-Vicrobeck, F. Maurice, M. Bonin, A. Perez Luna, C. J. Bournaud, G. Bégis, WO2006024784, 2006.
26. a) S. Yoshizawa, D. Fourmy, R. G. Eason, J. D. Puglisi, Biochemistry 2002, 41, 6263-6270; see also reference [7].
27. Lys3 is not stereospecific, and racemic ligands can be used in this approach. For the enantioselective preparation of 1, see: a) A. Pérez Luna, M.-A. Ceschi, M. Bonin, L. Micouin, H.-P. Husson, S. Gougeon, G. Estenne Bouthou, B. Marabout, M. Sevrin, P. George, J. Org. Chem. 2002, 67, 3522-3524;
28. b) A. Pérez Luna, M. Bonin, L. Micouin, H.-P. Husson, J. Am. Chem. Soc. 2002, 124, 12 098-12 099.